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Medicine, University of Illinois, Chicago, Illinois, USADepression is highly prevalent and is associated with poor quality of life and increased mortality among
adults with chronic kidney disease (CKD), including those with end-stage renal disease (ESRD). However,
there are several important differences in the diagnosis, epidemiology, and management of depression
between patients with nondialysis-dependent CKD and ESRD. Understanding these differences may lead
to a better understanding of depression in these 2 distinct populations. First, diagnosing depression using
self-reported questionnaires may be less accurate in patients with ESRD compared with CKD. Second,
although the prevalence of interview-based depression is approximately 20% in both groups, the risk
factors for depression may vary. Third, potential mechanisms of depression might also differ in CKD
versus ESRD. Finally, considerations regarding the type and dose of antidepressant medications vary
between CKD and ESRD. Future studies should further examine the mechanisms of depression in both
groups, and test interventions to prevent and treat depression in these populations.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).D epression is well known to affect adults with end-stage renal disease (ESRD), in part attributed to
psychosocial and biologic changes that accompany
dialysis.1,2 Recent studies have shown that patients
with chronic kidney disease (CKD) who are not on dial-
ysis have rates of depression up to 3 times higher than
those in the general population.3 Furthermore, depres-
sion has been associated with poor quality of life and
adverse medical outcomes in patients with CKD or
ESRD.4–8 In this narrative Review, we will examine
existing data and explore the similarities and differ-
ences in the diagnosis, epidemiology, and management
of depression in patients with CKD and those with
ESRD treated with maintenance dialysis (renal trans-
plant recipients and patients who chose conservative
management over dialysis or transplantation werespondence: Shayan Shirazian, 200 Old Country Road, Suite
ineola, New York 11501, USA. E-mail: sshirazian@winthrop.
ved 9 June 2016; revised 12 September 2016; accepted 13
mber 2016; published online 19 September 2016excluded from this Review). In addition, we will sug-
gest areas for future research aimed at furthering our
understanding of the causal pathways of depression
in CKD and ESRD, and evaluating interventions to pre-
vent and/or treat depression in these populations.
DIAGNOSIS
The Diagnostic and Statistical Manual of Mental Dis-
orders (DSM), published by the American Psychiatric
Association, is the standard set of criteria used to di-
agnose mental disorders in the United States.9 The
majority of studies examining the prevalence of uni-
polar depression (without mania or psychosis) in CKD
and ESRD through clinical interview have used the
DSM to deﬁne depressive disorders.3 These studies
have often used a broad deﬁnition of depression that
encompasses several different depressive disorders
from the DSM, including persistent depressive dis-
order (PDD), depressive disorder not otherwise speci-
ﬁed (NOS), and major depressive disorder (MDD).
These depressive disorders are brieﬂy deﬁned in
Table 1.Kidney International Reports (2017) 2, 94–107
Table 1. DSM-V classiﬁcation of depressive disorders9
- Major depressive disorder (MDD): a clinical syndrome lasting at least 2 weeks, where
patients experience either depressed mood or anhedonia, and at least 4 other
symptoms of depression.a Symptoms need to cause signiﬁcant distress and
impairment in one’s life, and cannot be caused by substance abuse or another
psychological or medical condition including mania.
- Persistent depressive disorder (PDD): depressed mood that occurs most days for at
least 2 years, and the presence of at least 2 of the following 6 symptoms: change in
appetite, insomnia or hypersomnia, fatigue, low energy, poor concentration or difﬁculty
making decisions, and feelings of hopelessness. These symptoms may not be caused
by substance abuse or a general medical condition, and must cause signiﬁcant
distress or impairment in one’s life. Previously known as dysthymia.
- Depressive disorder NOS: any depressive disorder that does not meet criteria for a
speciﬁc depressive disorder like PDD or MDD. Depressive disorder NOS was previously
broken up into distinct depressive disorders including minor depressive disorder.
- Minor depression: no longer a diagnostic classiﬁcation and now classiﬁed as
depressive disorder NOS in DSM-V. Previously deﬁned as a clinical syndrome of
depressed mood that lasted at least 2 weeks with at least 2 but fewer than 5 of the
symptoms required to diagnose MDD
DSM-V, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; NOS: not
otherwise specified.
aSymptoms of depression include weight loss, insomnia or hypersomnia, psychomotor
agitation or retardation, fatigue, feelings of worthlessness or guilt, diminished ability to
think, concentrate, or make decisions, and recurrent suicidal ideation.
S Shirazian et al.: Depression and Kidney Disease REVIEWThe gold standard to diagnose depression is the
clinical interview, including the following: (1) the
Structured Clinical Interview for DSM Disorders
(SCID)10; (2) the Composite International Diagnostic
Interview (CIDI)11; and (3) the Mini-International
Neuropsychiatric Interview (MINI).12 However, self-
reported questionnaires are often used in clinical and
research settings for screening of depressive symptoms.
The most commonly used depression screening ques-
tionnaires that have been validated for use in patients
with CKD and ESRD are as follows: Patient Health
Questionnaire (PHQ-9)13; Beck Depression Inventory
(BDI)13,14; Center for Epidemiologic Studies Depression
Scale (CESD)14; and Quick Inventory of Depressive
Symptomatology Self-Report (QIDS-SR).15
Several studies have validated depression-screening
questionnaires in patients with ESRD.13,14,16 In a
study of 98 patients with ESRD on hemodialysis by
Hedayati et al., the BDI and CESD scales were validated
against the SCID for diagnosing a depressive disorder
(MDD, dysthymia, or minor depression).14 A BDI cutoff
of 14 had a sensitivity of 62% and a speciﬁcity of 81%
for identifying a depressive disorder. The corre-
sponding sensitivity and speciﬁcity for a CESD cutoff
of 18 were 69% and 83%, respectively. Both cutoff
scores were higher than cutoffs set for the general
population (10 for the BDI and 16 for the CESD). In a
similar study by Watnick et al., the BDI and PHQ-9
were validated against the SCID for the diagnosis of a
depressive disorder (MDD, dysthymia or minor
depression).13 A BDI score of 16 and a PHQ-9 cutoff of
10 had sensitivity of 91% and 92%, respectively, and
speciﬁcity of 86% and 92%, respectively. As in the
study by Hedayati et al., the most accurate cutoff scoreKidney International Reports (2017) 2, 94–107for diagnosing a depressive disorder using the BDI was
higher than in the general population. This was
attributed to the overlap between somatic symptoms of
depression and symptoms related to ESRD, including
anemia, fatigue, difﬁculty concentrating, difﬁculty
sleeping, and poor appetite. Thus, patients with uremic
symptoms may screen positive for depression with a
self-reported questionnaire. However, these uremic
symptoms can be distinguished from depressive
symptoms during a clinical interview. For this reason,
the clinical interview remains the gold standard for
diagnosing depression in patients with ESRD.
Only 1 study has validated questionnaires to screen
for depression in patients with CKD.15 In this study of
272 patients with stage 2 to 5 CKD, Hedayati et al.
validated the BDI, and QIDS-SR(16) against the MINI.15
The authors found that the optimal cutoffs for
diagnosing a major depressive episode using the BDI
and QIDS-SR(16) were the same as the general
population, $11 and $10, respectively. However, the
inclusion of patients with CKD stages 2 and 3, who are
less likely to experience symptoms related to kidney
disease, could have inﬂuenced the results. Future
studies to validate depression-screening questionnaires
in patients with advanced CKD (stages 4 and 5) for
depressive disorders are needed.
Screening Strategies
Two potential strategies for screening depression in
patients with CKD and ESRD are generally used.17,18
The ﬁrst, a conservative approach, is to screen only
patients with signs of depression. These signs may
include social isolation (withdrawal from family,
friends, and social gatherings), changes in mood or
physical functioning, and/or increasing physical
complaints (sleep disturbance, decreased self-care,
including poorer compliance with medical follow-up
and dialysis). The second, a more aggressive strategy,
is to screen all new CKD or ESRD patients periodically
(every 6 months to 1 year) for depression with
screening questionnaires (either the PHQ-9 or BDI).
Speciﬁc health care providers, namely, a nurse,
social worker or physician, should be trained on a
protocol for administering depression screening ques-
tionnaires, including how to appropriately triage pa-
tients. Questionnaires, particularly items evaluating
suicidal ideation, should be reviewed prior to patients
leaving the clinic or dialysis center. Patients who
screen positive for depression should be referred to a
qualiﬁed professional to conﬁrm the diagnosis with a
clinical interview. Patients who require immediate
referral to a mental health professional or emergency
psychiatric services include those with suicidal95
REVIEW S Shirazian et al.: Depression and Kidney Diseaseideation, plan, or intent and those with depression
complicated by psychosis or mania.18
EPIDEMIOLOGY
Prevalence of Depression in CKD and ESRD
Depression is highly prevalent in patients with CKD
and ESRD. A recent systematic review and meta-
analysis by Palmer et al. examined the prevalence of
depression in these populations.3 The authors identi-
ﬁed 216 studies of 55,982 patients with CKD or ESRD.
Among patients with ESRD receiving dialysis, the
summary prevalence of depression was 39.3% when
evaluated by screening questionnaires, and 22.8%
when evaluated by clinical interview. In patients with
CKD, the summary prevalence of depression was 26.5%
when evaluated by screening questionnaires, and
21.4% when evaluated by clinical interview. Preva-
lence rates were higher in ESRD than in CKD when
questionnaires were used to diagnose depression
(39.3% vs. 26.5%), but were similar when depression
was diagnosed by clinical interview (22.8% vs.
21.4%). This difference is likely related to uremic
symptoms (fatigue, insomnia, poor appetite) in ESRD
populations that could overlap with somatic symptoms
of depression when measured using questionnaires.18
Since the publication of this meta-analysis, several
studies evaluating the prevalence of depressive symp-
toms in CKD using screening questionnaires have been
published (Table 2).4–7,19–23 The largest study to date,
by Fischer et al., reported a prevalence of depressive
symptoms of 27.4% using a BDI cutoff of 11 among
3853 individuals with mild-to-moderate CKD enrolledTable 2. Recent studies evaluating prevalence and outcomes of depress
First author, year, ref Sample characteristics
Measurement tool for
depression
Depres
prevale
Hedayati, 201022 267 Patients with
stage 2–5 CKD
DSM-IV interview
(MDE diagnosis)
21%
Fischer, 20117 628 Patients with
stage 2–4 CKD
BDI-II score > 14 or $11 26 or 4
Kop, 201119 5785 Patients, average GFR 78 CES-D $ 8 21.2
Cukor, 20124 70 Patients with stage 1–4 CKD BDI-II score $14 30%
Fischer, 201220 3853 Patients with
stage 2–4 CKD
BDI-II score $ 11 27.4
Tsai, 20126 428 Patients with
stage 3–5 CKD
BDI-II score $ 11 37%
Lee, 20135 208 Patients with
stage 3–5 CKD
HADS-D $ 8 47.1
Chiang, 201523 262 Patients (60.3% stage 4
and above)
Taiwanese Depression
Questionnaire
21%
AKI, acute kidney injury; BDI, Beck Depression Inventory; CESD, Center for Epidemiologic Stud
Manual of Mental Disorders, 4th edition; ESRD, end-stage renal disease; GFR, glomerular ﬁltr
hazard ratio; MDE, major depressive episode; QOL, quality of life; ref, reference.
96in the Chronic Renal Insufﬁciency Cohort (CRIC) and
Hispanic CRIC (HCRIC) studies.20
Prevalence of Depression in Minorities
People who belong to a minority racial/ethnic group
(e.g., black, Hispanic) have been shown to have higher
incident rates of CKD and ESRD compared with non-
Hispanic white individuals.24,25 Unfortunately, few
studies have evaluated the prevalence of depressive
symptoms in minority patients with CKD or
ESRD.7,19,20,26–28 In their analysis of 1600 black and 490
Hispanic patients from the CRIC and HCRIC studies,
Fischer et al. found that Hispanics had a 1.65 times
higher odds of depression, and that blacks had a 1.43
times higher odds of depression compared with non-
Hispanic white participants.20 Furthermore, both
black and Hispanic individuals were signiﬁcantly less
likely to use antidepressant medications compared with
non-Hispanic whites. Similarly, an analysis of 628
black individuals with CKD and HTN from the African-
American Study of Kidney Disease and Hypertension
(AASK) cohort found a 42% depression prevalence,
much higher than that observed in other mixed race/
ethnicity CKD populations.3,7 A higher risk of depres-
sion has been seen in other studies examining minor-
ities with CKD19 but has not been seen in ESRD
populations. Studies of patients with ESRD examining
the effects of race/ethnicity have yielded conﬂicting
results, either showing higher rates of depression
among whites or revealing no effect of race/ethnicity
on depression.26,29 In an analysis of 5256 persons with
ESRD on hemodialysis from the Dialysis Outcomes andion in CKD
sion
nce Follow-up Outcomes of depression
1 yr - Composite of death, hospitalization, or ESRD: HR ¼ 1.86
- Hospitalization: HR ¼ 1.90
- ESRD: HR 3.51
2% 5 yr - Composite of CV death or hospitalization
% 14 yr - AKI
6 mo - Worse QOL, social support, community integration
- Greater decline in GFR
% None
4 yr - Composite of ESRD or death: HR ¼ 1.66
- First hospitalization: HR ¼ 1.59
- Faster GFR decline
- Initial dialysis at a higher GFR
% None - Worse QOL
3 yr - Composite of dialysis or death: HR ¼ 2.95
- ESRD: HR ¼ 2.25
- Mortality: HR 3.08
ies Depression Scale; CKD, chronic kidney disease; DSM IV, Diagnostic and Statistical
ation rate; HADS-D, Hospital Anxiety and Depression Scaledepression subscale; HR,
Kidney International Reports (2017) 2, 94–107
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were signiﬁcantly less likely than white participants to
have physician-diagnosed depression.26 Epidemiology
and clinical studies thus far have revealed differing
effects of race/ethnicity on depression in patients with
CKD versus ESRD. Further studies examining this un-
expected ﬁnding, especially studies examining the ef-
fects of race/ethnicity on depression in patients with
ESRD, are needed.
Comparison to Other Populations
The prevalence of depression is 3 to 4 times higher in
patients with CKD and ESRD compared with the general
population and 2 to 3 times higher compared to in-
dividuals with other chronic illnesses. In the general
population, the lifetime risk of depression is estimated to
be between 5% and 10%.30–32 Rates of depression with
a comorbid medical illness are even higher. For patients
with diabetes, prevalence rates are between 12% and
18%; for patients with coronary artery disease (CAD),
rates are between 15% and 23%, and for patients with
chronic obstructive pulmonary disease, the estimated
prevalence of depression is around 25%.32,33
Depression and Outcomes
End-Stage Renal Disease
The majority of studies in patients with ESRD have
reported an association between depression and poor
psychosocial and medical outcomes, with only a mi-
nority reporting no association. In a recent systematic
review, Farrokhi et al. identiﬁed 31 studies of 67,075
patients examining the association between depression
and mortality in patients with ESRD receiving long-
term dialysis.34 Eighteen studies were limited to he-
modialysis patients; 4 included only peritoneal dialysis
patients; and 9 included both modalities. The authors
found that the mortality risk in patients on dialysis was
1.5 times higher in the presence of depressive symp-
toms independent of other confounding factors. They
also found that this relationship was dose dependent,
that is, the more severe the depression, the higher the
risk of mortality.
A study by Hedayati et al., which was not included
in the systematic review because it reported a composite
outcome, is the only study that evaluated the association
of depression diagnosed by a clinical interview and
clinical outcomes in patients with ESRD.35 In this study,
98 patients with ESRD undergoing chronic hemodialysis
underwent a SCID, and 26 were classiﬁed as depressed
(MDD, dysthymia, or minor depression). Patients were
followed up for 1 year, and 52 reached the primary
outcome (a composite of death or ﬁrst hospitalization).
The adjusted hazard ratio for the primary outcome was
2.07 in patients with depression.Kidney International Reports (2017) 2, 94–107In addition to mortality, depression in patients with
ESRD has been signiﬁcantly associated with other
adverse medical outcomes, including emergency
department visits,28 hospitalizations,28,36 cumulative
hospital days,36 cardiovascular events,37 peritonitis,38
and withdrawal from dialysis and suicide.39 In an
evaluation of 162 patients on peritoneal dialysis
assessed with BDI at 6-month intervals, Troidle et al.
found that a BDI score $11 was signiﬁcantly associated
with Gram-positive peritonitis.38 Moreover, in an
analysis of data from the US Renal Data System
(USRDS), Kurella et al. reported that suicide rates
among patients with ESRD on long-term dialysis were
signiﬁcantly higher compared with those in the general
population, and hospitalization due to a mental illness
in the preceding 12 months was signiﬁcantly associated
with withdrawal from dialysis and suicide.39
Depression has also been associated with poor psy-
chosocial outcomes in patients with ESRD. In a study of
the AASK cohort, higher depressive symptoms were
independently and signiﬁcantly associated with lower
quality of life.27 Furthermore, depressive symptoms
have been signiﬁcantly associated with fatigue,40
pain,41 pruritus,42 sleep disturbances,43,44 and sexual
dysfunction.45
Chronic Kidney Disease
Recent studies of patients with CKD who are not on
dialysis have reported an association between depres-
sion and adverse medical outcomes, including hospi-
talization,22 acute kidney injury,19 kidney function
decline,6 ESRD,23 and mortality.6,7,22,23 These studies
are summarized in Table 2. Hedayati et al. performed 1
of the most rigorous studies of medical outcomes in
patients with major depression and CKD.22 In this
study, 267 consecutively recruited patients with stage
2 to 5 CKD underwent a MINI interview, and 56 had a
current major depressive episode. All participants were
followed up for 1 year to monitor for the development
of the composite primary outcome (death, dialysis, or
hospitalization). At the end of 1 year, the adjusted
hazard ratio (95% conﬁdence interval [CI]) for the
primary outcome was 1.86 (1.23–2.84) in patients with
a major depressive episode. In another prospective
study of 628 AASK cohort participants with CKD (42%
with elevated depressive symptoms), baseline, time-
varying, and cumulative elevated depressive symp-
toms were signiﬁcantly associated with the composite
outcome of cardiovascular death or cardiovascular
hospitalization, but not with a composite kidney
outcome or all-cause mortality.7
Studies have reported an association of depression
with kidney function decline.6,9 A prospective study
by Tsai et al. evaluated the effect of depressive97
REVIEW S Shirazian et al.: Depression and Kidney Diseasesymptoms on renal outcomes in 568 patients with
CKD,6 of whom 160 had depressive symptoms (BDI
$ 11). Over a mean follow-up of 2 years, individuals
with depressive symptoms were 1.7 times more likely
to experience the primary outcome (progression to
ESRD or death) compared with those without depres-
sive symptoms. In addition, the presence of depressive
symptoms was associated with a faster rate of decline in
estimated glomerular ﬁltration rate.
A few recent studies have found an association be-
tween CKD and adverse psychosocial outcomes
including quality of life,4,5,46,47 poor social support,4
and sexual dysfunction.45 In a study by Cukor et al.
of 70 patients with CKD, including 21 patients with
depressive symptoms (BDI $14),4 patients with
depression had signiﬁcantly less integration into the
community, less social support, and lower quality of
life than patients without depression.4 More studies of
the effects of mild-to-moderate CKD on psychosocial
outcomes are needed at this time.ETIOLOGY OF DEPRESSION IN CKD AND ESRD
Potential explanations for the high burden of depres-
sion observed in patients with CKD and ESRD can be
divided into those related to primary (unrelated to
medical illness), and secondary (related to medical
illness) forms of depression. The underlying mecha-
nisms of primary depression in patients with kidney
disease are beyond the scope of this Review, and are
probably similar to those described in the general
population.48 Unfortunately, few studies have directly
examined the mechanisms of secondary depression in
patients with CKD and ESRD. However, potential
mechanisms can be gleaned from studies examining
risk factors for depression in these populations, and
from studies examining mechanisms of depression in
other chronic illnesses.
Demographic, Socioeconomic, and Clinical Risk
Factors for Depression
In patients with ESRD, factors that have been associ-
ated with depression include younger age, female
gender, white race, longer duration of dialysis, and
comorbid conditions such as diabetes, CAD, cerebro-
vascular disease, and peripheral vascular disease.36,49
In patients with CKD, similar risk factors are associ-
ated with depression, including younger age, female
gender, black race, Hispanic ethnicity, lower educa-
tion, lower family income, unemployment, hyperten-
sion, smoking status, diabetes, and CAD.6,9–21,50 In the
general population, lower socioeconomic status and
comorbid conditions have also been associated with
higher prevalence of depression51; however, because98these risk factors occur more frequently in patients
with kidney disease compared with the general popu-
lation, it is likely that they in part explain the higher
prevalence of depression seen in patients with kidney
disease compared with the general population.52,53
Mechanisms of Depression
In patients with diabetes and CAD, a bidirectional
association with depression has been found.32 For
example, depressive symptoms have been associated
with incident diabetes, and patients with clinically
identiﬁed diabetes have higher odds of developing
depressive symptoms than patients without diabetes.54
The directionality of the relationship between depres-
sive symptoms and CKD is unknown but is likely
bidirectional as well. Prior reviews suggest that several
of the underlying mechanisms of depression in CKD are
similar to those seen in other chronic illnesses and can
be divided into behavioral and biological mecha-
nisms.17,32,55 Figure 1 depicts behavioral and biological
mechanisms explaining the association between
depression and CKD and between depression and
adverse outcomes in this population.
Behavioral
The increased burden of self-care related to CKD and
ESRD, including frequent clinic and hospital visits, di-
etary restrictions, increased pill burden, and home
monitoring of glucose, blood pressure, and weight, may
lead to depression.48,56 This is added to the challenges
associated with dialysis, such as traveling to the dialysis
clinic 3 times weekly for hemodialysis, or performing
daily home hemodialysis or peritoneal dialysis. These
challenges can be particularly overwhelming for adults
for whom dialysis has recently been initiated. In an
analysis of 160 incident dialysis patients, depressive
symptoms soon after dialysis initiation were indepen-
dently associated with mortality.57
Functional impairment,46 and physical symptoms
caused by chronic illness, may also contribute to the
development of depression.48 For patients with CKD and
ESRD, comorbid conditions such as dementia, prior
stroke, or heart failure can limit daily activities. For
patients with ESRD, orthostasis, headache, and fatigue
after hemodialysis can prevent patients from performing
routine tasks. As described above, physical symptoms
related to uremia, dialysis treatment, and/or medications
(e.g., gastrointestinal distress from phosphate binders)
are frequently experienced by these patients, and have
been associated with depression. It remains unclear
whether these symptoms cause depression or whether
depression causes somatic symptoms.
In patients with both CKD and ESRD, the psycho-
logical burden of having an illness that affects futureKidney International Reports (2017) 2, 94–107
Figure 1. Mechanisms of depression and adverse medical outcomes.
S Shirazian et al.: Depression and Kidney Disease REVIEWmorbidity and mortality may lead to depression. This
may be even more relevant for patients with CKD who
have to cope with thoughts of impending dialysis or
transplantation.32,58
Depression may contribute to the development of
CKD through higher rates of adverse health risk be-
haviors such as smoking, sedentarism, and obesity.32
These behaviors are common in patients with CKD,
and may worsen pre-existing diabetes, hypertension,
or CAD, leading to CKD or CKD progression.59–62
Interestingly, there appears to be a protective associa-
tion of alcohol consumption, which is highly prevalent
among patients with depression,63 with the risk of
developing CKD.64
Finally, patients with ESRD have been shown to
withdraw from family and social support and to have
economic difﬁculties,52 both of which have been asso-
ciated with depression in this population.51,52 In a
study of 210 dialysis patients, of whom 100 had at least
1 prior episode of elevated depressive symptoms,
12.8% reported family or other personal issues, and
10.7% reported ﬁnancial difﬁculties as contributing
factors to depression.56
Biological
Several studies have supported a bidirectional associ-
ation between inﬂammation and depression in chronic
illness.32 This association is particularly relevant for
patients with CKD and ESRD, in whom inﬂammatory
levels are high,65 and for whom inﬂammation appears
to predict poor health outcomes such as CKD progres-
sion and mortality.65,66Kidney International Reports (2017) 2, 94–107Another potential biological mechanism that may
lead to depression in patients with CKD and ESRD is
the direct effect of comorbid cerebrovascular disease,
which is highly prevalent in patients with kidney
disease,67 on the mood regulatory functions of the
brain.68 For example, speciﬁc poststroke lesions in the
left anterior and left basal ganglia, and those close to
the frontal pole, have been associated with depres-
sion.68 Cerebrovascular disease may also indirectly
affect mood by increasing inﬂammation.48,68
Mechanisms by Which Depression Associates
With Adverse Outcomes
There are several potential biologic mechanisms that can
explain the association between depression and poorer
medical outcomes in patients with CKD and ESRD. As
described, depression can increase inﬂammation, which
in turn can accelerate atherosclerosis and potentially lead
to cardiovascular events.55 Depression is also implicated
in the modulation of vascular tone by altering serotonin
levels and autonomic nervous system function,
increasing platelet aggregation, altering cortisol and
norepinephrine production, all of which can lead to
cardiovascular events and stroke.55
There are also behavioral consequences of depres-
sion, which may adversely affect medical outcomes. In
patients with ESRD, depression has been associated
with medication noncompliance,69 dietary indiscre-
tion,55 interdialytic weight gain,55 and missed dial-
ysis.28,70 In a study of 65 hemodialysis patients and
94 kidney transplant patients, Cukor et al. evaluated
the association between psychological measures and99
REVIEW S Shirazian et al.: Depression and Kidney Diseaseself-reported medication adherence,69 and found that
depressive symptoms were a signiﬁcant independent
predictor of lower medication adherence. Furthermore,
in a study of 295 hemodialysis patients by Kimmel
et al., worsening depressive symptoms were correlated
with worse compliance with total dialysis time.70
Noncompliance with self-care behaviors could worsen
blood pressure, blood glucose, cholesterol, bone meta-
bolism, anemia, phosphorus, and volume status in pa-
tients with CKD and ESRD, and ultimately lead to
adverse health outcomes.
TREATMENT
Depression is undertreated in both patients with CKD
and those with ESRD. In an analysis of 1099 adults with
CKD stage 3 to 4 and elevated depressive symptoms who
were enrolled in the CRIC and HCRIC studies, only 31%
reported receipt of antidepressant medication.20 In
another study of 928 adults with ESRD on long-term
hemodialysis and physician-diagnosed depression,
only 34.9%were receiving antidepressant medication.49
Depression Treatment in Chronic Illness
In the general population and in patients with chronic
illness, treatment with antidepressants or psychother-
apy signiﬁcantly improves depressive symptoms and
psychosocial outcomes,71–73 and treating with a com-
bination of both has been shown to be more effective
than either alone.74 The impact of depression treatment
on other medical outcomes has been evaluated in
several studies, with mixed results.75–80 Interestingly,
studies of collaborative care models (psychiatric treat-
ment, delivered by a mental health specialist and a case
manager, combined with medical care), have shown
consistent improvements in medical outcomes.75,81,82
The safety and efﬁcacy of depression treatment in
patients with CKD or ESRD cannot be extrapolated from
prior studies of patients with other chronic illnesses
because elevated serum creatinine is often an exclusion
criterion in such studies,80 and because the pharmaco-
kinetics of antidepressant medications vary depending
on the level of kidney function.83 Unfortunately, few
studies have examined the safety and efﬁcacy of treating
depression in patients with CKD or ESRD, and these
studies are limited by small sample sizes, lack of control
groups, and selection and drop-out bias.84 A recent sys-
tematic reviewbyPalmer et al. concluded that data on the
beneﬁts and harms of antidepressant therapy in patients
with ESRD are sparse and currently inconclusive.85
Pharmacokinetics of Antidepressant
Medications in Kidney Disease
In general, antidepressant medications are protein
bound, have large volumes of distribution, and are100metabolized by the liver.18 These characteristics make
them unlikely to be removed by dialysis.18 There are,
however, important ways in which impaired kidney
function modiﬁes the pharmacokinetics of antidepres-
sant medications.83 Gastric alkalinization caused by
elevated urea levels and changes in gastrin, as well as
the use of phosphate binders or antacids, can decrease
the oral bioavailability of antidepressants. Volume
overload often observed in patients with CKD and
ESRD can alter the volume of distribution of antide-
pressants. Retention of uremic solutes can change the
albumin-binding characteristics of antidepressants and
increase their free fraction. Kidney disease may slow
their chemical degradation. Finally, for antidepressants
with any degree of renal clearance, excretion may be
impaired. Unfortunately, few studies have evaluated
the optimal dosing of antidepressants in patients with
abnormal kidney function.84 In general, providers
should monitor closely for side effects and drug in-
teractions whenever they are administered to patients
with kidney disease.
In a systematic review by Nagler et al., 28 studies
evaluating pharmacokinetics of antidepressants in CKD
or ESRD were identiﬁed.84 The authors reported that
drug clearance was markedly reduced for selegiline,
amitriptylinoxide (metabolite of amitriptyline), ven-
lafaxine, desvenlafaxine (metabolite of venlafaxine),
milnacipran, bupropion, reboxetine, and tianeptine.
The review also found that no studied antidepressants
were substantially removed by dialysis. A brief review
of the pharmacokinetics of selected antidepressant
classes is provided below, and dosing guidelines are
summarized in Table 3.
Most of the data on pharmacokinetics of antide-
pressant medications in CKD or ESRD comes from
studies of selective serotonin reuptake inhibitors
(SSRIs), which have shown that ESRD has no effect on
the pharmacokinetics of ﬂuoxetine, its active metabo-
lite norﬂuoxetine, or citalopram.86 However, exposure
to paroxetine is signiﬁcantly prolonged when the
creatinine clearance is <30 ml/min compared to >60
ml/min.86,87
Selective serotononinnorepinephrine reuptake in-
hibitors (SNRIs), such as venlafaxine, have been used
to treat depression and neuropathic pain in patients
with CKD and ESRD.86 The clearance of these medica-
tions is reduced in patients with ESRD, and therefore it
is recommended that their dose be reduced by 50%.86
A pharmacokinetics study of 12 individuals with ESRD
and 12 healthy controls found that the clearance of
duloxetine was more than 2 times longer in patients
with ESRD compared with controls.88 The product
insert for duloxetine in the United States currently
recommends not using this medication when theKidney International Reports (2017) 2, 94–107
Table 3. Antidepressant medication safety, dosing, and efﬁcacy in CKD and ESRD
Drug class,
generic
Dose in CKD
1--484 Dose in CKD 5 and ESRD84 Efﬁcacy studies Class adverse effects84-86
Selective serotonin reuptake inhibitor (SSRI): Common:
Insomnia, restlessness,
nausea, headache, GI
upset, sexual dysfunction,
activation (mainly with
ﬂuoxetine and sertraline)
Rare:
SIADH, increased bleeding
risk, extrapyramidal
symptoms, serotonin
syndrome (in combination
with other serotonergic
drugs), and QT
prolongation (seen with
doses >40 mg of
citalopram)
Sertraline No dosage adjustment
required:
50–200 mg/d
Similar to CKD 1–4. Start at
25 mg/d and consider
decreasing maximum dose
Three prospective efﬁcacy studies:
- 50 Patients with depression on HD were randomized to sertraline or
placebo. At the end of 12 wk, sertraline signiﬁcantly improved BDI-II scores
(47.5% reduction)108
- In a study by Wuerth et al., 22 patients on PD with interview-based
depression were included, and 11 patients completed a 12-week course
of therapy with an antidepressant medication (7 sertraline, 2 bupropion,
and 2 nefazodone). BDI scores decreased signiﬁcantly from a mean of
17.1 to 8.6109
- 25 Patients with interview-deﬁned depression on PD received sertraline 50
mg/d for 12 wk. BDI scores signiﬁcantly improved from 22.4 to 15.7110
Paroxetine IR:10–40 mg/d111
CR:12.5–50 mg/d112
Similar to CKD 1–4 - 34 Patients with MDD received paroxetine and psychotherapy for 8 wk.
Intervention signiﬁcantly improved depressive symptoms (HRSD 16.6 to
15.1 prepost treatment) and nutritional markers113
Citalopram No dosage adjustment
required: 10–40 mg/d
Use with caution: no
recommendation available
- 44 Patients on hemodialysis with a HADS score $8 were randomly
assigned to citalopram 20 mg/d for 3 mo or psychological training. Both
citalopram and psychological training signiﬁcantly reduced HADS scores
at the end of 3 mo114
Fluoxetine No dosage adjustment
required: 20–60 mg/d
Similar to CKD 1–4 Two prospective efﬁcacy studies:
- 6 Depressed patients on hemodialysis completed 8 wk of treatment with
20 mg ﬂuoxetine. Fluoxetine improved depressive symptoms by more than
25%115
- 14 Patients with major depression and on dialysis were randomly
assigned to treatment with ﬂuoxetine or placebo for 8 wk. Improvement in
depression was statistically signiﬁcant at 4 wk but not 8 wk89
Escitalopram No dosage adjustment
required: 10–20 mg/d116
Use with caution: no dosage
recommendation available
- 58 ESRD patients were randomized to escitalopram or placebo. Escita-
lopram signiﬁcantly improved HRDS scores compared to placebo117
Tricyclics (TCA) Anticholinergic effects,
orthostasis, sedation,
cardiotoxicity
Imipramine No dosage adjustment
required: 100–300 mg/day
Similar to CKD 1–4 No efﬁcacy data
Nortriptyline No dosage adjustment
required: 75–150 mg/d
Similar to CKD 1-4 No efﬁcacy data
Desipramine No dosage adjustment
required: 100–300 mg/d
Use with caution—effects of
metabolite accumulation
- 8 Patients with ESRD on dialysis with major depression treated with
desipramine for 7 wk. Recovery of major depression in 5 of 8 patients118
Serotonin-norepinephrine reuptake inhibitor (SNRI) Similar to SSRIs plus
increased BP. Liver toxicity
seen with duloxetine
Venlafaxine Normal dosage: 75–225 mg/d
eGFR 10–70: consider reducing
total daily dose 25%–50%:
150–225 mg/d119
Reduce total daily
dose by 50%
No efﬁcacy data
Duloxetine No adjustment required if eGFR
> 30: 40–120 mg/d
Use not recommended
with eGFR < 30
No efﬁcacy data
Miscellaneous Appetite stimulation, weight
gain, sedationMirtazapine No dosage adjustment
recommended: 15–45 mg/d
Consider dose reduction;
clearance reduced by 50%
No efﬁcacy data
Norepinephrine-dopamine reuptake inhibitors Increased risk of seizures,
insomnia, anxiety,
decreased appetite
Bupropion Consider reduced dose
and/or frequency:
150–450 mg/d120
Same as CKD 1–4 Wuerth et al. described above; 2 patients were treated with bupropion109
BDI, Beck Depression Inventory; BP, blood pressure; CKD, chronic kidney disease; CR, controlled release; ESRD, end stage renal disease; GI, gastrointestinal; HADS, Hospital Anxiety
and Depression Scale; HD, hemodialysis; HRSD, Hamilton Rating Scale for Depression; IR, immediate release; MDD, major depressive disorder; PD, peritoneal dialysis; SIADH, syndrome
of inappropriate antidiuretic hormone; SS, serotonin syndrome.
S Shirazian et al.: Depression and Kidney Disease REVIEWcreatinine clearance is <30 ml/min, due to decreased
clearance by the kidneys.86 However, regulatory
agencies outside the United States have suggested that
it can be used at lower doses with careful titration.88
Bupropion is a norepinephrinedopamine reuptake
inhibitor and a nicotinic antagonist used to treat
depression and aid with smoking cessation. Pharma-
cokinetics studies of bupropion in CKD and ESRD pa-
tients are limited, but metabolites appear to accumulate
in patients with ESRD, and dose reduction is likely
necessary.86Kidney International Reports (2017) 2, 94–107Mirtazapine is a noradrenergic and speciﬁc seroto-
nergic antidepressant medication that has been used to
treat depression and anxiety. It is also reported to have
hypnotic effects and appetite stimulant effects.
Although pharmacokinetic data are limited, it is likely
that mirtazapine accumulates in individuals with CKD
and ESRD and that dose reduction is therefore
necessary.86
Although pharmacokinetic data and efﬁcacy data
exist for tricyclic antidepressants (TCAs) and mono-
amine oxidase inhibitors (MAOIs), both classes of101
REVIEW S Shirazian et al.: Depression and Kidney Diseasemedications and their metabolites can accumulate with
impaired kidney function and cause serious side effects
(Table 3).86 In addition, several severe drugdrug in-
teractions, including use with other antidepressant
medications, limit the utility of MAOI.18 For these
reasons, both TCA and MAOI should not be considered
ﬁrst-line treatment for depression in patients with
kidney disease.18
Efﬁcacy Studies
In their systematic review, Nagler et al. identiﬁed 11
studies (1 randomized controlled trial [RCT], 1 abstract
of an RCT, and 9 nonrandomized trials) evaluating the
efﬁcacy of antidepressants in patients with ESRD.84
The trials were small (ranging from 7 to 62 partici-
pants) and possibly confounded by selection and drop-
out bias. None of these trials evaluated the efﬁcacy of
antidepressants in patients with CKD who were not
treated with dialysis. The majority evaluated SSRIs.
The sole published RCT, which enrolled 14 patients on
hemodialysis, showed no difference in efﬁcacy or
safety measures between ﬂuoxetine and placebo.89 All
9 noncontrolled, nonrandomized trial studies reported
a beneﬁt of antidepressants. The authors concluded
that evidence of effectiveness of antidepressants in
patients with stage 3 to 5 CKD (including ESRD) was
insufﬁcient. Since the publication of the above review,
Palmer et al. published a systematic review of RCTs
comparing the efﬁcacy of antidepressant medication
versus placebo or psychological training in patients
with ESRD.85 This review included 3 additional RCTs
not included in the review by Nagler et al. In all 3
RCTs, SSRIs signiﬁcantly improved depressive symp-
toms. Trials evaluating the efﬁcacy of antidepressants
in kidney disease are summarized in Table 3.
More data are needed prior to making deﬁnitive
recommendations on the efﬁcacy of antidepressants in
patients with kidney disease. We identiﬁed 4 ongoing
clinical trials (3 enrolling patients with ESRD, and 1
enrolling patients with CKD not on dialysis) examining
their effectiveness (Table 4).90,91 Hopefully, moreTable 4. Ongoing trials of depression treatment interventions from Clinica
Authors Sample characteristics Intervention
Hedayati et al.91 180 Patients with MDE and
stage 3–5 CKD not on dialysis
RCT of sertraline versus
Delgado et al.90 40 HD patients with MDE RCT of ﬂuoxetine versus b
Jassal et al.90 60 Incident dialysis patients
(within 12 wk of ﬁrst dialysis treatment)
RCT of escitalopram versu
Mehrotra et al.90 400 HD patients with MDE or dysthymia
underwent an engagement interview
180 HD patients with MDE or dysthymia
randomized to intervention
Individual CBT versus s
CKD, chronic kidney disease; HD, hemodialysis; MDE, major depressive episode; QIDS-C-16, 16
controlled trial.
aAll entries updated in 2016.
102efﬁcacy data will emerge soon. Based on current data,
we agree with recommendations by Hedayati et al. and
Kimmel et al. that SSRIs should be considered the ﬁrst
line of treatment for depression in patients with kidney
disease.17,18
Nonpharmacological Interventions
Cognitive-Behavioral Therapy (CBT) is a structured
psychotherapy intervention designed to treat
dysfunctional cognitions, negative emotions, and mal-
adaptive behaviors that are present in patients with
depression. Several studies of CBT in patients with
ESRD (none in CKD) have shown an improvement of
depressive symptoms with its use.92–94 In a random-
ized, crossover trial of 65 patients on hemodialysis,
Cukor et al. evaluated the effects of 10 individual CBT
sessions in participants with elevated depressive affect
(BDI-II > 10), delivered by a psychologist over 3
months.94 At the end of treatment, only 11% of pa-
tients in the treatment-ﬁrst group were depressed,
compared with 62% in the waitlist group. These results
are consistent with a 9-month RCT of 85 dialysis pa-
tients in which CBT signiﬁcantly improved depressive
symptoms and quality of life compared to control.93
In addition to treating depression, CBT has success-
fully improved quality of life, sleep quality, inﬂam-
mation, and adherence to ﬂuid restrictions in patients
with ESRD.93–95
Several trials have evaluated the effect of exercise
therapy and increased dialysis frequency on depres-
sive symptoms in patients with ESRD, with mixed
results.96–99 A recent review of exercise interventions
in patients with ESRD found 4 RCT in which depres-
sive symptoms were measured.96 In 3 of 4 of these
interventions, exercise improved depressive symptoms.
With regard to increasing dialysis frequency, the
largest study to date evaluated depressive symptoms
and mental health in 245 hemodialysis patients from the
Frequent Hemodialysis Network trials and 83 patients
from the Nocturnal Trials. Frequent (6 times weekly)
hemodialysis was found to improve self-reportedlTrials.gov90,91,a
Follow-up Primary outcomes
placebo 12 wk Depressive symptom severity as measured by the QIDS-C-16
upropion 12 wk Depression severity as measured by the 25-item HDRS
s placebo 26 wk Recruitment rates and protocol compliance
Secondary outcomes: adverse events, hospitalization days,
mortality, and changes in depression and QOL
ertraline 12 wk Percentage of patients who initiate treatment
Depressive symptom severity as measured by the QIDS-C-16
-item Quick Inventory of Depressive Symptomatology–clinician rated; RCT, randomized
Kidney International Reports (2017) 2, 94–107
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months.97 However, in a recent systematic review by
Slinin et al., 7 studies (2 RCT) evaluating the effect of
more frequent hemodialysis on depression were iden-
tiﬁed.99 The authors concluded that increasing dialysis
frequency did not improve clinical outcomes including
depression. For all studies evaluating the effect of
exercise or more frequent dialysis on depression, a
diagnosis of depression was not required for study
entry. It remains unclear whether patients with pre-
existing depression would beneﬁt from these
interventions, as these individuals may lack the moti-
vation to engage in exercise or more frequent dialysis.
Barriers to Treatment
There are several barriers to treatment in patients with
depression and CKD or ESRD. Perhaps in part because
of the already high medication burden in these pa-
tients, at least 40% of patients may not want treatment
for their depression.91,100,101 Furthermore, those who
accept behavioral treatment may not be willing to
follow certain recommendations, such as home exer-
cises, for the treatment to be successful.91 In addition,
nephrologists often do not start therapy for depression
in their patients with CKD or ESRD because they
believe that this is the responsibility of the primary
care provider.101,102 In a cross-sectional survey study
of hemodialysis providers by Green et al., less than
20% of providers reported treating known sexual
dysfunction or depression “most” or “all” of the time,
and 82% believed that it was the responsibility of the
primary care provider to manage depression.102 This is
particularly problematic for the 65% to 80% of he-
modialysis patients who do not have primary care
providers.101,103,104 Finally, combined behavioral and
medical interventions often require resources that are
not readily available at a CKD clinic or dialysis center,
including psychologists able to deliver behavioral
therapy in multiple languages. Ultimately, novel
treatment strategies that incorporate behavioral tech-
niques into routine medical care such as cognitive-
behavioral strategies integrated with CKD education
are needed. This model has been successfully used in
patients with diabetes and other chronic illnesses.81,105
FUTURE STUDIES
There are many gaps that remain in our understanding
of depression in patients with CKD and ESRD. We ﬁnd
that the most pressing areas of research involve un-
derstanding the mechanisms of depression and pre-
venting and treating depression in these populations.
With regard to the mechanisms of depression, current
research has not elucidated causative factors for
depression or the direction of the relationship betweenKidney International Reports (2017) 2, 94–107CKD and depression. Understanding these mechanisms
could help to both prevent and treat depression. With
regard to treatment, no large, well-designed studies
have evaluated depression prevention and treatment
interventions in patients with CKD or ESRD. This
paucity of data may be due, in part, to prioritization of
medical outcomes, such as progression to ESRD, over
patient-centered outcomes such as quality of life or
mood disorders, by the nephrology community.106
There is reason for optimism, however. Recently, the
Patient-Centered Outcomes Research Institute (PCORI)
has funded several clinically focused trials in patients
with kidney disease that are designed to engage pa-
tients in clinical kidney research.107 We hope that this
new focus on patient-centered outcomes in clinical
kidney research will lead to a greater understanding of
how depression affects patients with kidney disease,
and whether depression treatment will improve their
mood, quality of life, and medical outcomes.
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